Skip to main navigation Skip to search Skip to main content

The hippocampus as a central hub in ketamine’s antidepressant action: from molecules to circuit rewiring

  • Dongsun Park
  • , Gwangho Lee
  • , Bokyum Kim
  • , Minjoo Seong
  • , Ji Woon Kim

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Ketamine has emerged as a rapid-acting antidepressant that challenges classical monoaminergic frameworks and highlights the importance of synaptic and circuit-level plasticity in mood regulation. This review examines the hippocampus as a key site through which ketamine exerts both rapid and sustained antidepressant effects. We synthesize evidence showing that ketamine enhances hippocampal synaptic plasticity via mechanisms including NMDAR blockade of spontaneous neurotransmission, BDNF–TrkB signaling, MeCP2-dependent transcriptional priming, and adult neurogenesis. Molecular modulators such as Reelin, which influence NMDAR signaling and synaptic function, may also shape the efficacy of ketamine in a subset of individuals. Importantly, these hippocampal effects occur in coordination with broader network interactions, particularly with the medial prefrontal cortex and lateral habenula, allowing for circuit-level integration of antidepressant responses. Notably, ketamine’s therapeutic actions are dissociable from normalization of hypothalamic–pituitary–adrenal (HPA) axis function, underscoring a shift away from neuroendocrine-based models. By integrating molecular, synaptic, and systems-level findings, this review provides a hippocampus-centered framework for understanding ketamine’s antidepressant mechanisms and outlines novel strategies for circuit-informed, fast-acting antidepressant development.

Original languageEnglish
Pages (from-to)537-547
Number of pages11
JournalNeuropsychopharmacology
Volume51
Issue number3
DOIs
Publication statusPublished - Feb 2026

Bibliographical note

Publisher Copyright:
© The Author(s), under exclusive licence to American College of Neuropsychopharmacology 2025.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'The hippocampus as a central hub in ketamine’s antidepressant action: from molecules to circuit rewiring'. Together they form a unique fingerprint.

Cite this